Since the 2018 Farm Bill legalized hemp, there are now two distinct commercial industries: pharmaceuticals / wellness and industrial. In the pharmaceutical and consumer wellness areas, there is an explosion of innovation and new products. In the industrial market, there is increasing interest in light of sustainability and carbon capture considerations.
Focusing on the Cannabis Administration and Opportunity Act (CAOA), the Marijuana Opportunity Reinvestment and Expungement Act (MORE), and the States Reform Act (SRA), our panelists will discuss how these proposals would change how the the relevant agencies (such as USDA, FDA, TTB, and PTO) regulate the cannabis sector.
Our distinguished panel of judges will hear argument from both sides—petitioners and the government—and make a decision regarding the legality of marijuana’s continued classification as a Schedule I substance. Come see the exciting hearing unfold!
This CLE explores whether a mark owner has used its mark to sell improperly labeled soap or an illicit drug, the PTO has no mandate, and no convincing policy reason, to deny the owner the substantial benefits of registration.